<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="91298b84-e636-4b4d-8848-593964f9c8d5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CEFAZOLIN IN DEXTROSE INJECTION safely and effectively.  See full prescribing information for CEFAZOLIN IN DEXTROSE INJECTION.<br/>
      <br/>CEFAZOLIN IN DEXTROSE injection, for intravenous use<br/>Initial U.S. Approval: 1973</title>
   <effectiveTime value="20240531"/>
   <setId root="d91a8d13-99a0-4d87-88dc-71cbd37922b4"/>
   <versionNumber value="15"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194684502" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3508" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3503" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0096" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3508" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3503" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0096" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3508" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3503" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0096" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3508" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3503" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0096" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3508" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-3503" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0096" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <relatedDocument typeCode="RPLC">
      <relatedDocument>
         <id root="5ba13e5d-93a6-40fb-b085-7a0038bf33da"/>
         <setId root="13a33420-b1e1-4b7e-8e59-4d5badafe654"/>
         <versionNumber value="18"/>
      </relatedDocument>
   </relatedDocument>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="1a53f58a-6026-4023-9356-572c54503128"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240531"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-3508" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefazolin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefazolin Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="2"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="P380M0454Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFAZOLIN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IHS69L0Y4T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFAZOLIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="4"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BICARBONATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-3508-41" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20150807"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA207131" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150807"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-3503" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefazolin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefazolin Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="1"/>
                              <denominator unit="mL" value="50"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="P380M0454Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFAZOLIN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IHS69L0Y4T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFAZOLIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="2"/>
                              <denominator unit="mL" value="50"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BICARBONATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="24"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-3503-41" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20150807"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA207131" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150807"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-0096" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefazolin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefazolin Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="3"/>
                              <denominator unit="mL" value="150"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="P380M0454Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFAZOLIN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IHS69L0Y4T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFAZOLIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="6"/>
                              <denominator unit="mL" value="150"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BICARBONATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="150"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="6"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-0096-06" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240531"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA207131" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240531"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_7DEFB022-E4C8-4E06-B61E-36D1D51A20AD">
               <id root="0bade7f4-c6bc-48b4-89e2-7bde3b957258"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Indications and Usage, Perioperative Prophylaxis (<linkHtml href="#ID_3bc42c49-3dbc-4741-a34e-14c64a76dc2b">1.9</linkHtml>)	 2/2024</paragraph>
                        <paragraph>Dosage and Administration, Important Administration Instructions (<linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">2.1</linkHtml>) 5/2024</paragraph>
                        <paragraph>Dosage and Administration, Dosage for the Treatment of Infections (<linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>) 5/2024</paragraph>
                        <paragraph>Dosage and Administration, Dosage for Perioperative Prophylaxis (<linkHtml href="#ID_df3617e1-19d0-4985-832f-dab2ac77cf99">2.3</linkHtml>) 5/2024</paragraph>
                        <paragraph>Warnings and Precautions, Prothrombin Activity (<linkHtml href="#ID_d90638cc-e08b-4b01-bf1f-271a7d3878ae">5.5</linkHtml>) 	2/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_7434f430-d746-428d-8920-d3d907283944">
               <id root="fb079536-a518-4a10-b92f-576023c02c13"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20240531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is a cephalosporin antibacterial indicated for: </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Treatment of the following infections caused by susceptible isolates of the designated microorganisms <content styleCode="underline">in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved</content>: (<linkHtml href="#ID_7434f430-d746-428d-8920-d3d907283944">1</linkHtml>) <list listType="unordered">
                                 <item>
                                    <caption>ο</caption>Respiratory tract infections (<linkHtml href="#ID_cf2a7491-54d0-44d3-87fb-397a00ab33c5">1.1</linkHtml>);</item>
                                 <item>
                                    <caption>ο</caption>Urinary tract infections (<linkHtml href="#ID_7372226b-37d8-499e-88de-2013c1ddc796">1.2</linkHtml>);</item>
                                 <item>
                                    <caption>ο</caption>Skin and skin structure infections (<linkHtml href="#ID_33e0bc32-8419-4f55-98c4-a1224de8c746">1.3</linkHtml>);</item>
                                 <item>
                                    <caption>ο</caption>Biliary tract infections (<linkHtml href="#ID_b4420aae-47d2-46a8-9a31-7c2b726aaf08">1.4</linkHtml>);</item>
                                 <item>
                                    <caption>ο</caption>Bone and joint infections (<linkHtml href="#ID_91d52044-8dd5-410a-9e5a-0d1b1a219769">1.5</linkHtml>);</item>
                                 <item>
                                    <caption>ο</caption>Genital infections (<linkHtml href="#ID_3a43f347-921c-4be4-a72a-75437acc7405">1.6</linkHtml>);</item>
                                 <item>
                                    <caption>ο</caption>Septicemia (<linkHtml href="#ID_0813e752-bc47-415b-a6e9-91b10e3516b6">1.7</linkHtml>);</item>
                                 <item>
                                    <caption>ο</caption>Endocarditis (<linkHtml href="#ID_656fbd68-04dd-41c3-88eb-5bf31738d521">1.8</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Perioperative prophylaxis in adults <content styleCode="underline">and pediatric patients aged 10 to 17 years old for whom appropriate dosing with this formulation can be achieved</content> (<linkHtml href="#ID_3bc42c49-3dbc-4741-a34e-14c64a76dc2b">1.9</linkHtml>) </item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin in Dextrose Injection and other antibacterial drugs, Cefazolin in Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#ID_1af6494f-b1bc-484c-b461-0a8037078efd">1.10</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_cf2a7491-54d0-44d3-87fb-397a00ab33c5">
                     <id root="5685e983-94e1-4378-b7f9-5714ac160f31"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Respiratory Tract Infections </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of respiratory tract infections due to <content styleCode="italics">Streptococcus pneumoniae, Staphylococcus aureus </content>and <content styleCode="italics">Streptococcus pyogenes</content> in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved <content styleCode="italics">[see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.</paragraph>
                        <paragraph>Cefazolin in Dextrose Injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7372226b-37d8-499e-88de-2013c1ddc796">
                     <id root="b853f886-65ce-43c0-b14b-2fda602a0f92"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Urinary Tract Infections </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of urinary tract infections due to <content styleCode="italics">Escherichia coli, </content>and <content styleCode="italics">Proteus mirabilis </content>in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved <content styleCode="italics">[see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_33e0bc32-8419-4f55-98c4-a1224de8c746">
                     <id root="629e9968-7aaa-4503-83bf-14860644d30d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Skin and Skin Structure Infections </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of skin and skin structure infections due to <content styleCode="italics">S. aureus</content>, <content styleCode="italics">S. pyogenes</content>, and <content styleCode="italics">Streptococcus agalactiae </content>in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved <content styleCode="italics">[see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b4420aae-47d2-46a8-9a31-7c2b726aaf08">
                     <id root="66522559-f917-44f4-a8c8-4304eecf4488"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Biliary Tract Infections </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of biliary infections due to <content styleCode="italics">E. coli</content>, various isolates of streptococci, <content styleCode="italics">P. mirabilis, </content>and <content styleCode="italics">S. aureus</content> in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved <content styleCode="italics">[see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_91d52044-8dd5-410a-9e5a-0d1b1a219769">
                     <id root="e8de070e-9dcd-4515-a998-46feb64f6951"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.5 Bone and Joint Infections  </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of bone and joint infections due to <content styleCode="italics">S. aureus</content> in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved <content styleCode="italics">[see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3a43f347-921c-4be4-a72a-75437acc7405">
                     <id root="4d07e13c-9d06-431a-af12-c97b1dca3a5b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.6 Genital Infections </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of genital infections due to <content styleCode="italics">E. coli, </content>and <content styleCode="italics">P. mirabilis</content> in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved <content styleCode="italics">[see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0813e752-bc47-415b-a6e9-91b10e3516b6">
                     <id root="1f13c408-84f5-4db8-b016-fe1d522ff363"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.7 Septicemia </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of septicemia due to <content styleCode="italics">S. pneumoniae, S. aureus</content>, <content styleCode="italics">P. mirabilis, </content>and <content styleCode="italics">E. coli</content> in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved <content styleCode="italics">[see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_656fbd68-04dd-41c3-88eb-5bf31738d521">
                     <id root="1695ece4-6001-4028-a725-d1da1756d680"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.8 Endocarditis </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of endocarditis due to <content styleCode="italics">S. aureus </content>and <content styleCode="italics">S. pyogenes </content>in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved <content styleCode="italics">[see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3bc42c49-3dbc-4741-a34e-14c64a76dc2b">
                     <id root="1da0d19c-0c62-473c-9743-01a955e1dced"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">1.9 Perioperative Prophylaxis</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Cefazolin in Dextrose Injection is indicated for perioperative prophylaxis in adults and pediatric patients aged 10 to 17 years old for whom appropriate dosing with this formulation can be achieved [see <linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_df3617e1-19d0-4985-832f-dab2ac77cf99">2.3</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml>, <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The perioperative use of Cefazolin in Dextrose Injection is indicated in adult and pediatric (aged 10 to 17 years old) surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The prophylactic administration of Cefazolin in Dextrose Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones).</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1af6494f-b1bc-484c-b461-0a8037078efd">
                     <id root="f11d9898-8829-4ea3-aebc-01c565f08e68"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.10 Usage </title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin in Dextrose Injection and other antibacterial drugs, Cefazolin in Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7509d4aa-4e93-403d-840f-400afcb8fc5b">
               <id root="8e5af054-c240-4d23-8129-9464df370e2f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20240531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>If a dose of Cefazolin in Dextrose Injection is required that does not equal 1 gram, 2 grams or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered. (<linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">2.1</linkHtml>)<br/>For intravenous use only administered over approximately 30 minutes. (<linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">2.1</linkHtml>)</paragraph>
                        <table cellpadding="0pt" width="100%">
                           <col width="47%"/>
                           <col width="20%"/>
                           <col width="34%"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Recommended Dosing Schedule in Adult Patients with CLcr Greater Than or Equal To 55 m L/min. (<linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">2.1</linkHtml>)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Site and Type of Infection</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Dose</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Frequency</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Moderate to severe infections</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>500 mg to 1 gram</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>every 6 to 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Mild infections caused by susceptible gram-positive cocci</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>250 mg to 500 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>every 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Acute, uncomplicated urinary tract infections</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1 gram</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>every 12 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pneumococcal pneumonia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>500 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>every 12 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Severe, life-threatening infections (e.g., endocarditis, septicemia)<footnote ID="_Ref30677132">In rare instances, doses of up to 12 grams of cefazolin per day have been used</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1 gram to 1.5 grams</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>every 6 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="4" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>
                                       <br/>
                                       <br/>Perioperative prophylaxis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>less than 120 kg: 1 gram to 2 grams</paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>½ to 1 hour prior to start of surgery</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>greater than or equal to 120 kg: 3 grams</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>500 mg to 1 gram</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>additional dose during surgery for lengthy procedures</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>500 mg to 1 gram</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>every 6 to 8 hours for 24 hours postoperatively</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table cellpadding="0pt" width="100%">
                           <col width="34%"/>
                           <col width="29%"/>
                           <col width="37%"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Recommended Dosing Schedule in Pediatric Patients with CLcr Greater than or Equal to 70 mL/min. (<linkHtml href="#ID_d305579c-8ddb-4724-b882-abc871cf2250">2.1</linkHtml>, <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">2.2</linkHtml>, and <linkHtml href="#ID_df3617e1-19d0-4985-832f-dab2ac77cf99">2.3</linkHtml>)</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Site and Type of Infection</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Dose</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Frequency</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Moderate to severe infections<footnote ID="_Ref158820621">For the treatment indications (<linkHtml href="#ID_cf2a7491-54d0-44d3-87fb-397a00ab33c5">1.1</linkHtml> to <linkHtml href="#ID_656fbd68-04dd-41c3-88eb-5bf31738d521">1.8</linkHtml>)</footnote>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>25 to 50 mg per kg</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>divided into 3 or 4 equal doses</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Severe infections<footnoteRef IDREF="_Ref158820621"/>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>May increase to 100 mg<br/>per kg</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>divided into 3 or 4 equal doses</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Perioperative prophylaxis (10 to 17 years old)</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>less than 50 kg: 1 gram</item>
                                    </list>
                                 </td>
                                 <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>½ to 1 hour prior to start of surgery</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>greater than or equal to 50 kg: 2 grams</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>500 mg to 1 g </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>additional dose during surgery for lengthy procedures </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>500 mg to 1 g </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>every 6 to 8 hours for 24 hours postoperatively </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Dosage adjustment is required for adult patients with CLcr that is less than 55 mL/min and pediatric patients with CLcr that is less than 70 mL/min. (<linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_919771bc-e9c0-40c0-a9ea-0b2482171ca2">8.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>See full prescribing information for preparation and administration instructions. (<linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_d305579c-8ddb-4724-b882-abc871cf2250">
                     <id root="c77bb5ff-b953-47de-a031-b6a35d3fdde9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.1 Important Administration Instructions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">If a dose of Cefazolin in Dextrose Injection is required that does not equal 1 gram, 2 grams or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Administer Cefazolin in Dextrose Injection intravenously over approximately 30 minutes.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">
                     <id root="ac3419fa-5230-46f6-9de1-293a0de3e468"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage for the Treatment of Infections</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosage for the Treatment of Infections in Adults with Creatinine Clearance (CLcr) Equal to 55 mL/min or Greater</content>
                        </paragraph>
                        <paragraph>The recommended adult dosages for the treatment of infections [see <linkHtml href="#ID_cf2a7491-54d0-44d3-87fb-397a00ab33c5">Indications and Usage (1.1</linkHtml> to <linkHtml href="#ID_656fbd68-04dd-41c3-88eb-5bf31738d521">1.8)</linkHtml>] are outlined in <content styleCode="xmChange">
                              <linkHtml href="#_Ref169086477">Table 1</linkHtml>
                           </content> below. Administer Cefazolin in Dextrose Injection intravenously over approximately 30 minutes.</paragraph>
                        <table ID="_Ref169086477" styleCode="Noautorules" width="100%">
                           <caption>Table 1: Recommended Dosing Schedule in Adult Patients with CLcr Greater Than or Equal To 55 mL/min.<footnote ID="_Ref169084974">
                                 <content styleCode="xmChange">If a dose of Cefazolin in Dextrose Injection is required that does not equal 1 gram, 2 grams, or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered.</content>
                              </footnote>
                           </caption>
                           <col width="62%"/>
                           <col width="20%"/>
                           <col width="18%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Site and Type of Infection</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Dose</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Frequency</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Moderate to severe infections</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">500 mg to 1 gram</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">every 6 to 8 hours</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Mild infections caused by susceptible gram-positive cocci</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">250 mg to 500 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">every 8 hours</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Acute, uncomplicated urinary tract infections</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">1 gram</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">every 12 hours</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Pneumococcal pneumonia</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">500 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">every 12 hours</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Severe, life-threatening infections (e.g., endocarditis, septicemia)<footnote ID="_Ref169085067">
                                             <content styleCode="xmChange">In rare instances, doses of up to 12 grams of cefazolin per day have been used.</content>
                                          </footnote>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">1 gram to 1.5 grams</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">every 6 hours</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Dosage for the Treatment of Infections in Pediatric Patients with CLcr Equal to 70 mL/min or Greater</content>
                        </paragraph>
                        <paragraph>The recommended pediatric dosages for the treatment of infections [see <linkHtml href="#ID_cf2a7491-54d0-44d3-87fb-397a00ab33c5">Indications and Usage (1.1</linkHtml> to <linkHtml href="#ID_656fbd68-04dd-41c3-88eb-5bf31738d521">1.8)</linkHtml>] are outlined in <linkHtml href="#_Ref134713900" title="Table 2">Table 2</linkHtml> below. Administer Cefazolin in Dextrose Injection intravenously over approximately 30 minutes.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">If a dose of Cefazolin in Dextrose Injection is required that does not equal 1 gram, 2 grams, or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered [see <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                        <table ID="_Ref134713900" cellpadding="0pt" width="100%">
                           <caption>Table 2: Recommended Dosage in Pediatric Patients with CLcr 70 mL/min or greater for Treatment of Infections [see Indications and Usage (1.1 to 1.8)]</caption>
                           <col width="33%"/>
                           <col width="67%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Type of Severity</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Recommended Total Daily Dosage</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Mild to moderate infections</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>25 mg/kg to 50 mg/kg, divided into 3 or 4 equal doses</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Severe infections</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>May increase to 100 mg/kg, divided into 3 or 4 equal doses</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_df3617e1-19d0-4985-832f-dab2ac77cf99">
                     <id root="a28f049a-f51f-4502-a7b1-0032d30e24d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage for Perioperative Prophylaxis </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosage for Perioperative Prophylaxis in Adults with CLcr Equal to 55 mL/min or Greater</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended dosages are described in <linkHtml href="#_Ref158285250" title="Table 3">Table 3</linkHtml> below.</content>
                        </paragraph>
                        <table ID="_Ref158285250" cellpadding="0pt" width="100%">
                           <caption>Table 3: Recommended Dosage for Perioperative Prophylaxis in Adults with Clcr of 55 mL/min or Greater</caption>
                           <col width="18%"/>
                           <col width="32%"/>
                           <col width="25%"/>
                           <col width="24%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">
                                             <br/>Body Weight (kg)</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">Dose Administered (½ hour to 1 hour prior to the start of surgery)</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">Additional Dose During Lengthy Operative Procedures (e.g., 2 hours or more)</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">Dose for 24 Hours Postoperatively</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">Less than 120 kg</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange"> 1 gram to 2 grams</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">500 mg to 1 g</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">500 mg to 1 g every<br/>6 hours to 8 hours</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">Greater than or equal to 120 kg</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="xmChange">3 grams</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>If a dose of Cefazolin in Dextrose Injection is required that does not equal 1 gram, 2 grams or 3 grams, this product is not recommended, and an alternative formulation of cefazolin should be considered.</paragraph>
                        <paragraph>It is important that (i) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision; and (ii) cefazolin be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms.</paragraph>
                        <paragraph>The perioperative prophylactic administration of cefazolin should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of cefazolin may be continued for 3 to 5 days following the completion of surgery.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dosage for Perioperative Prophylaxis in Pediatric Patients Aged 10 to 17 Years Old with CLcr 70 mL/min or Greater</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are described in <linkHtml href="#_Ref158818454" title="Table 4">Table 4</linkHtml> below.</content>
                        </paragraph>
                        <table ID="_Ref158818454" styleCode="Noautorules" width="98.04%">
                           <caption>Table 4: Recommended Dosage for Perioperative Prophylaxis in Pediatric with CLcr 70 mL/min or greater Aged 10 to 17 years Old<footnote ID="_Ref158818455">
                                 <content styleCode="xmChange">If a dose of Cefazolin in Dextrose Injection is required that does not equal 1 gram or 2 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered.</content>
                              </footnote>
                           </caption>
                           <col width="25%"/>
                           <col width="26%"/>
                           <col width="26%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Body Weight (kg)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Dose Administered ½ Hour to 1 Hour Prior to the Start of Surgery</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Additional Dose During Lengthy Operative Procedures (e.g., 2 Hours or More)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Dose for 24 Hours Postoperatively</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Less than 50 kg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">1 g</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">500 mg to 1 g</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">500 mg to 1 g every 6 hours to 8 hours</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Greater than or equal to 50 kg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">2 g</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="xmChange">It is important that (i) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision; and (ii) cefazolin be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The administration of Cefazolin in Dextrose Injection for perioperative prophylaxis should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating the administration of Cefazolin in Dextrose Injection for perioperative prophylaxis may be continued for 3 days to 5 days following the completion of surgery.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e64494a6-29d5-4be0-a08f-2917a9765134">
                     <id root="f86c4e55-bf72-42fc-bba2-dacfa13d271f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Recommendations in Adult and Pediatric Patients with Renal Impairment</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosage Recommendations in Adult Patients with CLcr less than 55 mL/min</content>
                        </paragraph>
                        <paragraph>The dosage recommendation for Cefazolin in Dextrose Injection in adult patients with renal impairment (CLcr less than 55 mL/min) is outlined in <linkHtml href="#_Ref158285362" title="Table 5">Table 5</linkHtml> below.</paragraph>
                        <table ID="_Ref158285362" cellpadding="0pt" width="100%">
                           <caption>Table 5: Dosage Recommendation for Adult Patients with CLcr less than 55 mL/min</caption>
                           <col width="31%"/>
                           <col width="38%"/>
                           <col width="31%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Creatinine Clearance</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Dose</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Frequency</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>35 to 54 mL/min</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>Recommended dose</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>every 8 hours or longer</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>11 to 34 mL/min</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>Half of recommended dose<footnote ID="_Ref64028445">If the recommended dose in adult patients with creatinine clearance equal to 35 mL/min or greater is 1 gram, then this product is not recommended for use in patients with creatinine clearance less than 35 mL/min and an alternative formulation of cefazolin should be considered.</footnote>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>every 12 hours</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>10 mL/min or less</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>Half of recommended dose<footnoteRef IDREF="_Ref64028445"/>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>every 18 to 24 hours</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Dosage Recommendations in Pediatric Patients with CLcr less than 70 mL/min</content>
                        </paragraph>
                        <paragraph>The dosage recommendation for Cefazolin in Dextrose Injection in pediatric patients with renal impairment (CLcr less than 70 mL/min) is outlined in <linkHtml href="#_Ref158285393">Table 6</linkHtml> below.</paragraph>
                        <table ID="_Ref158285393" cellpadding="0pt" width="100%">
                           <caption>Table 6: Recommended Dosage in Pediatric Patients with CLcr less than 70 mL/min<footnote ID="_Ref169085615">If a dose of Cefazolin in Dextrose Injection is required that does not equal 1 gram, 2 or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered.</footnote>
                           </caption>
                           <col width="22%"/>
                           <col width="78%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Creatinine Clearance</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Recommended Dosage</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>40 to 70 mL/min</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>60% of the normal daily dose given in equally divided doses every 12 hours</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>20 to 40 mL/min</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>25% of the normal daily dose given in equally divided doses every 12 hours</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>5 to 20 mL/min</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption> </caption>10% of the normal daily dose every 24 hours</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f15627f6-7474-4cb2-92cd-0327db052096">
                     <id root="5687ec1e-0b61-485b-be46-7c191c365f83"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Preparation for Use of Cefazolin in Dextrose Injection </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Thawing of Plastic Container</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Thaw frozen container at room temperature 20°C to 25°C (68°F to 77°F) or under refrigeration 2°C to 8°C (36°F to 46°F). Product should not be thawed by immersion in water baths or by microwave irradiation. Do not force thaw. </item>
                           <item>
                              <caption>•</caption>No further dilution is necessary.</item>
                           <item>
                              <caption>•</caption>Check for minute leaks by squeezing container firmly. If leaks are detected, discard solution as sterility may be impaired.</item>
                           <item>
                              <caption>•</caption>Do not add supplementary medication.</item>
                           <item>
                              <caption>•</caption>The container should be visually inspected. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Components of the solution may precipitate in the frozen state and will dissolve upon reaching room temperature with little or no agitation. Potency is not affected. Agitate after solution has reached room temperature. If after visual inspection the solution remains cloudy or if an insoluble precipitate is noted or if any seals are not intact, the container should be discarded.</item>
                           <item>
                              <caption>•</caption>The thawed solution is stable for 30 days under refrigeration (5°C/41°F) or 48 hours at 25°C/77°F. <content styleCode="underline">Do not refreeze thawed antibacterial drugs.</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Preparation for Administration</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Suspend container from support.</item>
                           <item>
                              <caption>•</caption>Remove protector from outlet port at bottom of container.</item>
                           <item>
                              <caption>•</caption>Attach Intravenous administration set to outlet port. Refer to the manufacturer’s instructions accompanying the administration set for complete directions.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_0020e8eb-74c4-4320-8408-cf87512bd3e1">
               <id root="c4b0ca35-a157-4054-8518-9c3ee061cf70"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Injection: 1 gram cefazolin per 50 mL, 2 gram cefazolin per 100 mL or 3 gram cefazolin per 150 mL in a single-dose Galaxy container supplied as a frozen, premixed, iso-osmotic, sterile, nonpyrogenic solution.</paragraph>
               </text>
               <effectiveTime value="20240531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="underline">Injection</content>: 1 gram in 50 mL, 2 grams in 100 mL and 3 grams in 150 mL (<linkHtml href="#ID_0020e8eb-74c4-4320-8408-cf87512bd3e1">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_18d35601-46bb-48ea-a446-bd0c669ee59c">
               <id root="e3c8d352-ade3-4cde-9d12-f50c429eb569"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <effectiveTime value="20240201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (<linkHtml href="#ID_5d20ee4b-6a07-4a92-b51b-34369ec5632c">4.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_5d20ee4b-6a07-4a92-b51b-34369ec5632c">
                     <id root="c097d538-e287-4818-b832-ab01e980fc49"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Hypersensitivity to Cefazolin or the Cephalosporin Class of Antibacterial Drugs, Penicillins, or Other Beta-lactams</title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is contraindicated in patients who have a history of immediate hypersensitivity reactions (e.g., anaphylaxis, serious skin reactions) to cefazolin or the cephalosporin class of antibacterial drugs, penicillins, or other beta-lactams [<content styleCode="italics">see <linkHtml href="#ID_490fd910-4311-46aa-a865-64b0a8b04079">Warnings and Precautions (5.1)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_338f64e5-0082-48f4-b696-3f467510e72f">
               <id root="02cd7641-209b-4627-8e29-68f760449428"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20240531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: Cross-hypersensitivity may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction occurs, discontinue the drug. (<linkHtml href="#ID_490fd910-4311-46aa-a865-64b0a8b04079">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">
                                 <content styleCode="italics">Clostridioides difficile</content>-associated Diarrhea (CDAD)</content>: May range from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. (<linkHtml href="#ID_242eb65e-a75b-4ed3-aa2b-8e044bd007e5">5.3</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Prothrombin Activity</content>: May be associated with fall in prothrombin activity. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (<linkHtml href="#ID_d90638cc-e08b-4b01-bf1f-271a7d3878ae">5.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_490fd910-4311-46aa-a865-64b0a8b04079">
                     <id root="9cc9272d-cbc5-4b65-8820-4f1b7483fcfb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams </title>
                     <text>
                        <paragraph>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with Cefazolin in Dextrose Injection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefazolin, cephalosporins, penicillins, or carbapenems. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Cefazolin in Dextrose Injection occurs, discontinue the drug.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c0ce07d5-aa01-492f-b66e-3fa674f4b10a">
                     <id root="ac952703-d0e8-4948-b4e8-7780e88d6e3d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Seizures in Patients with Renal Impairment </title>
                     <text>
                        <paragraph>Seizures may occur with the administration of Cefazolin in Dextrose Injection, particularly in patients with renal impairment when the dosage is not reduced appropriately. Discontinue Cefazolin in Dextrose Injection if seizures occur or make appropriate dosage adjustments in patients with renal impairment <content styleCode="italics">[see <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">Dosage and Administration (2.4)</linkHtml>]</content>. Anticonvulsant therapy should be continued in patients with known seizure disorders.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_242eb65e-a75b-4ed3-aa2b-8e044bd007e5">
                     <id root="3c5c7f1c-b7ca-435c-bf39-0256e6b26778"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 <content styleCode="italics">Clostridioides difficile-</content>associated Diarrhea </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioide<content styleCode="bold">s</content> difficile</content>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefazolin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing isolates of <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20210201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_922d0f0f-8df0-4a16-96c5-88f099fc719d">
                     <id root="1d17c472-5066-4c3f-a63e-91e140a839fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hypersensitivity to Dextrose-containing Products</title>
                     <text>
                        <paragraph>Hypersensitivity reactions, including anaphylaxis, have been reported with administration of dextrose- containing products. These reactions have been reported in patients receiving high concentrations of dextrose (i.e. 50% dextrose)<sup>1</sup>. The reactions have also been reported when corn-derived dextrose solutions were administered to patients with or without a history of hypersensitivity to corn products.<sup>2</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d90638cc-e08b-4b01-bf1f-271a7d3878ae">
                     <id root="220e5cef-7024-4ec4-ad09-fa7dcea1a001"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.5 Prothrombin Activity </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Cefazolin in Dextrose Injection may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2a7894ee-d296-4a59-90fd-24c3c384225e">
                     <id root="4ed2f13f-2d08-4821-a3b2-12d315e8cbd0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Risk of Development of Drug-resistant Bacteria </title>
                     <text>
                        <paragraph>Prescribing Cefazolin in Dextrose Injection in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                        <paragraph>As with other antimicrobials, prolonged use of Cefazolin in Dextrose Injection may result in overgrowth of nonsusceptible microorganisms. Repeated evaluation of the patient's condition is essential. Should superinfection occur during therapy, appropriate measures should be taken.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a0000646-0ffa-4021-a5e7-1aa9c0f3b849">
                     <id root="1e0b220f-db75-411a-90f9-3e676a74f107"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Drug/Laboratory Test Interactions </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Urinary Glucose</content>
                        </paragraph>
                        <paragraph>The administration of Cefazolin in Dextrose Injection may result in a false-positive reaction with glucose in the urine when using glucose tests based on Benedict’s copper reduction reaction that determine the amount of reducing substances like glucose in the urine. It is recommended that glucose tests based on enzymatic glucose oxidase be used.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Coombs’ Test</content>
                        </paragraph>
                        <paragraph>Positive direct Coombs' tests have been reported during treatment with cefazolin.  In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibacterial drugs before parturition, it should be recognized that a positive Coombs' test may be due to the drug.</paragraph>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_255fcadf-ce3a-4155-aa4d-22d8e3af7459">
                     <id root="7f1e92f7-8859-425a-8767-d07530aa9073"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Patients with Overt or Known Subclinical Diabetes Mellitus or Carbohydrate Intolerance </title>
                     <text>
                        <paragraph>As with other dextrose-containing solutions, Cefazolin in Dextrose Injection should be prescribed with caution in patients with overt or known subclinical diabetes mellitus or carbohydrate intolerance for any reason.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_512437ca-acc9-4b01-997f-36950a7c0ee5">
               <id root="a13769b4-6456-49d8-8663-788ccf2cadb3"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious adverse reactions to Cefazolin in Dextrose Injection are described below and elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams [see <content styleCode="italics">
                           <linkHtml href="#ID_490fd910-4311-46aa-a865-64b0a8b04079">Warnings and Precautions (5.1)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>•</caption>Seizures in Patients with Renal Impairment <content styleCode="italics">[see <linkHtml href="#ID_c0ce07d5-aa01-492f-b66e-3fa674f4b10a">Warnings and Precautions (5.2)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Clostridioides difficile</content>-associated Diarrhea <content styleCode="italics">[see <linkHtml href="#ID_242eb65e-a75b-4ed3-aa2b-8e044bd007e5">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Adult and Pediatric Patients</content>: Most common adverse reactions: gastrointestinal (nausea, vomiting, diarrhea), and allergic reactions (anaphylaxis, urticaria, skin rash).  (<linkHtml href="#ID_512437ca-acc9-4b01-997f-36950a7c0ee5">6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Pediatric Patients with Perioperative Prophylaxis</content>: The most frequently reported adverse reactions (incidence ≥ 5%) were nausea, infusion site pain, and headache. (<linkHtml href="#ID_512437ca-acc9-4b01-997f-36950a7c0ee5">6</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or </content>
                           <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6cc2c1f7-fa17-490f-a241-77af8aaacaed">
                     <id root="4e1670d7-3f51-45c9-93c8-980392046763"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The following adverse reactions were reported from clinical trials:</paragraph>
                        <paragraph>Gastrointestinal: Diarrhea, oral candidiasis (oral thrush), mouth ulcers, vomiting, nausea, stomach cramps, epigastric pain, heartburn, flatus, anorexia and pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment <content styleCode="italics">[see <linkHtml href="#ID_242eb65e-a75b-4ed3-aa2b-8e044bd007e5">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Allergic: Anaphylaxis, eosinophilia, urticaria, itching, drug fever, skin rash, Stevens-Johnson syndrome.</paragraph>
                        <paragraph>Hematologic: Neutropenia, leukopenia, thrombocytopenia, thrombocythemia.</paragraph>
                        <paragraph>Hepatic: Transient rise in SGOT, SGPT, and alkaline phosphatase levels has been observed. Reports of hepatitis have been received.</paragraph>
                        <paragraph>Renal: Reports of increased BUN and creatinine levels, as well as renal failure, have been received.</paragraph>
                        <paragraph>Local Reactions: Instances of phlebitis have been reported at site of injection. Some induration has occurred.</paragraph>
                        <paragraph>Other Reactions: Pruritus (including genital, vulvar and anal pruritus, genital moniliasis, and vaginitis). Dizziness, fainting, lightheadedness, confusion, weakness, tiredness, hypotension, somnolence and headache.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions in Pediatric Patients for Perioperative Prophylaxis</content>
                        </paragraph>
                        <paragraph>Two studies (Study 1: NCT 3231228 and Study 2: NCT 01904357) were conducted to assess the safety and pharmacokinetics of a single 30-minute infusion of either 1 gram or 2 grams (based on weight) of cefazolin for injection and dextrose injection for perioperative prophylaxis in pediatric patients. </paragraph>
                        <paragraph>Study 1 was a multicenter, open-label, non-comparative, parallel group study to evaluate the safety and pharmacokinetics of a single 30-minute infusion of either 1 gram or 2 grams (based on weight) of cefazolin for injection and dextrose injection for perioperative prophylaxis in 61 pediatric patients 10 to 17 years of age. Thirty-three subjects with a weight of at least 25 kg but less than 60 kg received a single dose of 1 gram of cefazolin for injection and dextrose injection  and 28 subjects with a weight of at least 60 kg received a single dose of 2 grams of cefazolin for injection and dextrose injection. The mean age of the safety population was 14 years and ranged from 10 to 17 years. There were no adverse reactions leading to study discontinuation or deaths reported during the study. The most frequently reported adverse reactions were nausea (14.8%), infusion site pain (6.6%), and headache (4.9%).</paragraph>
                        <paragraph>Study 2 was a multicenter, non-comparative study that evaluated the safety and pharmacokinetics of a single 30-minute infusion of either 1 gram or 2 grams (based on weight) of cefazolin for injection  and dextrose injection for perioperative prophylaxis in 12 pediatric patients 10 to 12 years of age. Subjects weighing at least 25 kg to less than 50 kg received a single dose of 1 gram of cefazolin for injection and dextrose injection and subjects weighing at least 50 kg to less than 85 kg received a single dose of 2 grams of cefazolin for injection and dextrose injection. The safety findings in Study 2 in pediatric patients aged 10 to 12 years old were similar to those observed in adult patients and the pediatric patients aged 10 to 17 years old in Study 1.</paragraph>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f7450712-27f2-4deb-a5e8-e4dcf453ecd9">
                     <id root="1c6ff521-b72b-4725-b9f6-6dc0ae2d24e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of cefazolin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders: Serum sickness-like reaction</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and urinary disorders: Acute tubulointerstitial nephritis (ATIN)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders: Acute generalized exanthematous pustulosis (AGEP)</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210728"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d63482d2-be03-4aa3-93e2-9bc0fb14302f">
                     <id root="164d7fad-f0d0-499e-b9f1-0759cb7435e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Cephalosporin-class Adverse Reactions </title>
                     <text>
                        <paragraph>In addition to the adverse reactions listed above that have been observed in patients treated with cefazolin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterials: </paragraph>
                        <paragraph>Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal impairment, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, a fall in prothrombin activity, hepatic impairment including cholestasis, and pancytopenia.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7c87a302-360e-4dfd-89bd-0d13d1d5c8bf">
               <id root="6d050fbb-a26e-4250-8282-7f0c28d04384"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <text>
                  <paragraph>The renal excretion of cefazolin is inhibited by probenecid. Co-administration of probenecid with Cefazolin in Dextrose Injection is not recommended.</paragraph>
               </text>
               <effectiveTime value="20240201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Probenecid</content>: The renal excretion of cefazolin is inhibited by probenecid. Co-administration of probenecid with Cefazolin in Dextrose Injection is not recommended. (<linkHtml href="#ID_7c87a302-360e-4dfd-89bd-0d13d1d5c8bf">7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_b91d037b-3333-47b4-8bbf-cebe0537ec77">
               <id root="f5332cf4-9ff8-4bb8-9d90-70230206d47f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20240531"/>
               <component>
                  <section ID="ID_1ba1f4e0-2250-46a8-8d6a-e5c53c33debc">
                     <id root="872a34e1-182b-4e1b-a4ee-4a165d377925"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary<br/>
                           </content>Available data from published prospective cohort studies, case series and case reports over several decades with cephalosporin use, including cefazolin, in pregnant women have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Cefazolin crosses the placenta.</paragraph>
                        <paragraph>Animal reproduction studies with rats, mice and rabbits administered cefazolin during organogenesis at doses 1 to 3 times the maximum recommended human dose (MRHD) did not demonstrate adverse developmental outcomes. In rats subcutaneously administered cefazolin prior to delivery and throughout lactation, there were no adverse effects on offspring at a dose approximately 2 times the MRHD <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph ID="Data">
                           <content styleCode="underline">Data<br/>
                           </content>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>While available studies cannot definitively establish the absence of risk, published data from case-control studies and case reports over several decades have not identified an association with cephalosporin use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Reproduction studies have been performed in rats, mice and rabbits administered cefazolin during organogenesis at doses of 2000, 4000 and 240 mg/kg/day (approximately 1 to 3 times the maximum recommended human dose on a body surface area comparison). There was no evidence of any adverse effects on embryofetal development due to cefazolin. In a peri‑postnatal study in rats, cefazolin administered subcutaneously up to 1200 mg/kg/day (approximately 2 times the MRHD based on body surface area comparison) to pregnant dams prior to delivery and through lactation caused no adverse effects on offspring.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_367c463e-4f0d-4d06-9b7d-1c4b54603ca5">
                     <id root="738d40cc-cc75-46c6-92e1-4b2a43221d60"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary <br/>
                           </content>Data from published literature report that cefazolin is present in human milk, but is not expected to accumulate in a breastfed infant. There are no data on the effects of cefazolin on the breastfed child or on milk production.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cefazolin in Dextrose Injection and any potential adverse effects on the breastfed child from Cefazolin in Dextrose Injection or from the mother’s underlying condition.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_07afd558-282a-4cc6-994f-df148a8ea252">
                     <id root="9816b2c6-92db-49f1-a71a-77c429fba4ad"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Cefazolin in Dextrose Injection is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and skin structure infections, biliary tract infections, bone and joint infections, genital infections, septicemia, and endocarditis in pediatric patients for whom appropriate dosing with this formulation can be achieved and for perioperative prophylaxis in pediatric patients aged 10 to 17 years old <content styleCode="italics">[see <linkHtml href="#ID_cf2a7491-54d0-44d3-87fb-397a00ab33c5">Indications and Usage (1.1</linkHtml> to <linkHtml href="#ID_656fbd68-04dd-41c3-88eb-5bf31738d521">1.8</linkHtml>)]</content>.</paragraph>
                        <paragraph>Safety and effectiveness of Cefazolin in Dextrose Injection in premature infants and neonates have not been established and is not recommended for use in this age group of pediatric patients. Dosing for cefazolin in pediatric patients younger than one month old has not been established.</paragraph>
                        <paragraph>Because of the limitations of the available strengths and administration requirements (i.e., administration of fractional doses is not recommended) of Cefazolin in Dextrose Injection, and to avoid unintentional overdose, this product is not recommended for use if a dose of Cefazolin in Dextrose Injection that does not equal 1 gram or 2 grams is required and an alternative formulation of cefazolin should be considered <content styleCode="italics">[see <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#ID_7509d4aa-4e93-403d-840f-400afcb8fc5b">2</linkHtml>,<linkHtml href="#ID_0020e8eb-74c4-4320-8408-cf87512bd3e1">3</linkHtml>, <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">2.4</linkHtml> and <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">2.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of cefazolin for injection and dextrose injection for perioperative prophylaxis have been established in pediatric patients aged 10 to 17 years old. Use of cefazolin for injection and dextrose injection in these age groups is supported by evidence from adults with additional safety and pharmacokinetic data in pediatric patients aged 10 to 17 years old. Safety and pharmacokinetics were evaluated in two multicenter, non-comparative studies (Study 1 and Study 2). These studies were conducted to assess the safety and pharmacokinetics of a single 30-minute infusion of either 1 gram or 2 grams (based on weight) of cefazolin for injection and dextrose injection for perioperative prophylaxis in pediatric patients. Study 1 evaluated the safety and pharmacokinetics of 1 g of cefazolin for injection and dextrose injection in pediatric patients aged 10 to 17 years old scheduled for surgery with a weight of at least 25 kg but less than 60 kg and 2 g in pediatric patients with a weight of at least 60 kg. Study 2 evaluated 1 g of another cefazolin injection product in pediatric patients aged 10 to 12 years old scheduled for surgery with a weight of at least 25 kg but less than 50 kg and 2 g in pediatric patients with a weight of at least 50 kg to less than 85 kg <content styleCode="italics">[see <linkHtml href="#ID_df3617e1-19d0-4985-832f-dab2ac77cf99">Dosage and Administration (2.3)</linkHtml>, <linkHtml href="#ID_6cc2c1f7-fa17-490f-a241-77af8aaacaed">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#ID_b100ee86-c909-40f3-a2a0-25c1a5c708d2">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of Cefazolin in Dextrose Injection for perioperative prophylaxis have not been established in pediatric patients younger than 10 years old<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e75193e2-88b0-4738-834e-4b138dcab8ab">
                     <id root="f8deaea6-2deb-4ef5-94c8-a08aef60bd37"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the 920 subjects who received cefazolin in clinical studies, 313 (34%) were 65 years and over, while 138 (15%) were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <content styleCode="italics">[see <linkHtml href="#ID_df3617e1-19d0-4985-832f-dab2ac77cf99">Dosage and Administration (2.3)</linkHtml> and <linkHtml href="#ID_c0ce07d5-aa01-492f-b66e-3fa674f4b10a">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_919771bc-e9c0-40c0-a9ea-0b2482171ca2">
                     <id root="b1bd45f6-61c0-4110-8bab-081297f7d073"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Patients with Renal Impairment </title>
                     <text>
                        <paragraph>When Cefazolin in Dextrose Injection is administered to adult and pediatric patients with low urinary output because of impaired renal function (creatinine clearance less than 55 mL/min and 70 mL/min for adults and pediatric patients, respectively), lower daily dosage is required [<content styleCode="italics">see <linkHtml href="#ID_e64494a6-29d5-4be0-a08f-2917a9765134">Dosage and Administration (2.4)</linkHtml> and <linkHtml href="#ID_c0ce07d5-aa01-492f-b66e-3fa674f4b10a">Warnings and Precautions (5.2)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_217987C7-67FD-4FD5-8645-56658AE1B5C6">
               <id root="4f3ad944-1546-48a2-9cc5-8779c69c6355"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Accidental overdosage resulting in seizures may occur in patients with renal impairment who receive doses greater than the recommended dosage of Cefazolin in Dextrose Injection<content styleCode="italics"> [see <linkHtml href="#ID_c0ce07d5-aa01-492f-b66e-3fa674f4b10a">Warnings and Precautions (5.2)</linkHtml>]. </content>If seizures associated with accidental overdosage occur, discontinue Cefazolin in Dextrose Injection and give supportive treatment.</paragraph>
               </text>
               <effectiveTime value="20240201"/>
            </section>
         </component>
         <component>
            <section ID="ID_4b0f6bf3-f07e-45b9-a401-a6588f280de0">
               <id root="1b5b7598-dd00-40e2-91d7-756bec2c649e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Cefazolin in Dextrose Injection is a frozen, premixed, iso-osmotic, sterile, nonpyrogenic, single-dose solution containing either 1 g Cefazolin, USP, equivalent to 1.05 g Cefazolin Sodium, USP per 50 mL, 2 g Cefazolin, USP, equivalent to 2.1 g Cefazolin Sodium, USP per 100 mL or 3 g Cefazolin, USP, equivalent to 3.15 g Cefazolin Sodium, USP per 150 mL Galaxy container (PL 2040 Plastic).  Dextrose, USP has been added to adjust osmolality (4 % as dextrose hydrous).  The approximate osmolality for Cefazolin in Dextrose Injection is 290 mOsmol/kg.</paragraph>
                  <paragraph>Cefazolin Sodium is a semi-synthetic cephalosporin antibacterial for parenteral administration and has the following IUPAC nomenclature: Sodium (6R,7R)-3-[[(5-methyl-1,3,4- thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1<content styleCode="italics">H</content>-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2- ene-2-carboxylate.  Its molecular formula is C<sub>14</sub>H<sub>13</sub>N<sub>8</sub>O<sub>4</sub>S<sub>3</sub>·Na and its molecular weight is 454.51 (free acid).</paragraph>
                  <paragraph>Cefazolin Sodium USP has the following structural formula:</paragraph>
                  <renderMultiMedia ID="id668373444" referencedObject="ID_47c8eb2a-ad5f-4526-8e00-2a3901d046f9"/>
                  <paragraph>The sodium content is 48 mg/g of cefazolin sodium.</paragraph>
                  <paragraph>The pH of Cefazolin in Dextrose Injection may have been adjusted with sodium bicarbonate, or sodium hydroxide/hydrochloric acid during manufacture.  Water for injection, USP is added as drug vehicle.  Contains no preservative.  The solution is intended for intravenous use after thawing to room temperature.</paragraph>
                  <paragraph>This Galaxy container (PL 2040 Plastic) is fabricated from a specially designed multilayer plastic (PL 2040).  Solutions are in contact with the polyethylene layer of this container and can leach out certain chemical components of the plastic in very small amounts within the expiration period.  However, the suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies. </paragraph>
               </text>
               <effectiveTime value="20240531"/>
               <component>
                  <observationMedia ID="ID_47c8eb2a-ad5f-4526-8e00-2a3901d046f9">
                     <text>Cefazolin Sodium, USP Structural Formula.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1160e2a2-27fa-4aed-8136-e97cf5f3f198">
               <id root="e69bfc9b-378f-4afe-956e-6ed28874d972"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20240531"/>
               <component>
                  <section ID="ID_f8ed361a-b0d5-40cd-9dbd-21d8d220ccc6">
                     <id root="91b98d5c-910c-43dc-9602-d783ae14a48b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Cefazolin is an antibacterial drug [<content styleCode="italics">see <linkHtml href="#ID_df29a737-aad6-42ad-b759-c8a489a7d933">Microbiology (12.4)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20210201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c0e4c619-3f1e-494b-a5e0-5428e7cd2a09">
                     <id root="c0e4c619-3f1e-494b-a5e0-5428e7cd2a09"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>The pharmacokinetic/pharmacodynamic relationship for cefazolin has not been evaluated in patients.</paragraph>
                     </text>
                     <effectiveTime value="20150831"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b100ee86-c909-40f3-a2a0-25c1a5c708d2">
                     <id root="50bdeb38-bb46-4e6b-8d26-048c199d5344"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Studies have shown that following intravenous administration of cefazolin to normal subjects, mean serum concentrations peaked at approximately 185 mcg/mL and were approximately 4 mcg/mL at 8 hours for a 1 gram dose.</paragraph>
                        <paragraph>The serum half-life for cefazolin is approximately 1.8 hours following IV administration.</paragraph>
                        <paragraph>In a study of constant intravenous infusion with dosages of 3.5 mg/kg for 1 hour (approximately 250 mg) and 1.5 mg/kg the next 2 hours (approximately 100 mg), cefazolin serum concentrations at the third hour of approximately 28 mcg/mL.</paragraph>
                        <paragraph>Plasma pharmacokinetic parameters of cefazolin in healthy adult subjects (N=12) following a single 15- minute IV infusion of 2 grams of cefazolin for injection and dextrose injection are summarized in <linkHtml href="#_Ref158731545">Table 7</linkHtml>.</paragraph>
                        <table ID="_Ref158731545" styleCode="Noautorules" width="100%">
                           <caption>Table 7: Mean (Standard Deviation) Plasma Pharmacokinetic Parameters of Cefazolin in Healthy Adult Subjects</caption>
                           <col width="33%"/>
                           <col width="7%"/>
                           <col width="12%"/>
                           <col width="9%"/>
                           <col width="13%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <col width="9%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub>
                                          <br/>(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">T<sub>max</sub>
                                       </content>
                                       <footnote ID="_Ref158732251">T<sub>max</sub> reported as median (range)</footnote>
                                       <br/>
                                       <content styleCode="bold">(h)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>0-inf</sub>
                                          <br/>(mcg*h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">T<sub>1/2</sub>
                                          <br/>(h)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">CL<br/>(L/h)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">V<sub>z</sub>
                                          <br/>(L)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Single 2 grams Dose as a 15- Minute IV Infusion</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>280.9<br/>(45.9)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0.25<br/>(0.25-0.33)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>509.9<br/>(89.3)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>2.01<br/>(0.28)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>4.03<br/>(0.68)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>11.50<br/>(1.53)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>N= number of subjects observed; C<sub>max</sub> = maximum plasma concentration; T<sub>max</sub> = time to maximum plasma concentration; AUC<sub>0-inf</sub> = area under the plasma concentration-time curve extrapolated to infinity; t<sub>1/2</sub> = apparent plasma terminal elimination half-life; CL = total clearance; V<sub>z</sub> = volume of distribution</paragraph>
                        <paragraph>Plasma pharmacokinetic parameters of cefazolin in healthy adult subjects with a weight of greater than or equal to 120 kg (N=12) following a single 30-minute IV infusion of 3 grams of Cefazolin in Dextrose Injection are summarized in Table 8.</paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <caption>Table 8: Mean (Standard Deviation) Plasma Pharmacokinetic Parameters of Cefazolin in Healthy Adult Subjects ≥ 120 kg</caption>
                           <col width="33%"/>
                           <col width="7%"/>
                           <col width="12%"/>
                           <col width="9%"/>
                           <col width="13%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <col width="9%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub>
                                          <br/>(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">T<sub>max</sub>
                                       </content>
                                       <footnote ID="_Ref169086000">T<sub>max</sub> reported as median (range)</footnote>
                                       <br/>
                                       <content styleCode="bold">(h)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>0-inf</sub>
                                          <br/>(mcg*h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">T<sub>1/2</sub>
                                          <br/>(h)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">CL<br/>(L/h)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">V<sub>z</sub>
                                          <br/>(L)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Single 3 grams Dose as a 30-Minute IV Infusion</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>223<br/>(26.0)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0.55<br/>(0.54-1.26)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>585<br/>(76.5)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>2.29<br/>(0.28)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>5.20<br/>(0.67)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>17.0<br/>(1.54)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>N= number of subjects observed; C<sub>max</sub> = maximum plasma concentration; T<sub>max</sub> = time to maximum plasma concentration; AUC<sub>0-inf</sub> = area under the plasma concentration-time curve extrapolated to infinity; t<sub>1/2</sub> = apparent plasma terminal elimination half-life; CL = total clearance; V<sub>z</sub> = volume of distribution</paragraph>
                        <paragraph>Studies in patients hospitalized with infections indicate that cefazolin produces mean peak serum concentrations approximately equivalent to those seen in healthy subjects.</paragraph>
                        <paragraph>Bile concentrations in patients without obstructive biliary disease can reach or exceed serum concentrations by up to five times; however, in patients with obstructive biliary disease, bile concentrations of cefazolin are considerably lower than serum concentrations (less than 1.0 mcg/mL).</paragraph>
                        <paragraph>In synovial fluid, the cefazolin concentration becomes comparable to that reached in serum at about 4 hours after drug administration.</paragraph>
                        <paragraph>Studies of cord blood show prompt transfer of cefazolin across the placenta. Cefazolin is present in very low concentrations in the milk of nursing mothers.</paragraph>
                        <paragraph>Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients for Perioperative Prophylaxis </content>
                        </paragraph>
                        <paragraph>A simulation based on pharmacokinetic data from healthy adults (n=24), pediatric patients aged 10 to 17 years (n=26: Study 1 <content styleCode="italics">[see <linkHtml href="#ID_6cc2c1f7-fa17-490f-a241-77af8aaacaed">Adverse Reactions (6.1)</linkHtml>]</content>), and pediatric patients aged 10 to 12 years (n=12: Study 2 <content styleCode="italics">[see <linkHtml href="#ID_6cc2c1f7-fa17-490f-a241-77af8aaacaed">Adverse Reactions (6.1)</linkHtml>]</content> indicate that the administration of a 1 gram dose of cefazolin for injection and dextrose injection for pediatric patients weighing less than 50 kg and a 2 grams dose of cefazolin for injection and dextrose injection for those weighing 50 kg or greater will provide comparable exposures between pediatric patients aged 10 to 17 years and healthy adults receiving 2 grams Cefazolin in Dextrose Injection  <content styleCode="italics">[see <linkHtml href="#ID_fd2d9128-1d97-40fa-a0e6-f5bf76e66e8b">Dosage and Administration (2.2</linkHtml> and <linkHtml href="#ID_df3617e1-19d0-4985-832f-dab2ac77cf99">2.3</linkHtml>) and <linkHtml href="#ID_07afd558-282a-4cc6-994f-df148a8ea252">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_df29a737-aad6-42ad-b759-c8a489a7d933">
                     <id root="f9b231cd-fed2-4b7e-a3b5-3f88396d9152"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Cefazolin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                        </paragraph>
                        <paragraph>Predominant mechanisms of bacterial resistance to cephalosporins include the presence of extended- spectrum beta-lactamases and enzymatic hydrolysis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>Cefazolin has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [<content styleCode="italics">see <linkHtml href="#ID_7434f430-d746-428d-8920-d3d907283944">Indications and Usage (1)</linkHtml>
                           </content>].</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="underline">Gram-Positive Bacteria</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Staphylococcus aureus</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Staphylococcus epidermidis</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus agalactiae</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus pneumoniae</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus pyogenes</content>
                           </item>
                        </list>
                        <paragraph>Methicillin-resistant staphylococci are uniformly resistant to cefazolin.</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="underline">Gram-Negative Bacteria</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Escherichia coli</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Proteus mirabilis</content>
                           </item>
                        </list>
                        <paragraph>Most isolates of indole positive Proteus (<content styleCode="italics">Proteus vulgaris</content>), <content styleCode="italics">Enterobacter </content>spp., <content styleCode="italics">Morganella morganii, Providencia rettgeri, Serratia </content>spp., and <content styleCode="italics">Pseudomonas </content>spp. are resistant to cefazolin.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Testing</content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see: <linkHtml href="http://www.fda.gov/STIC">http://www.fda.gov/STIC.</linkHtml>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_574544ee-cb59-4726-a4b3-93057e5c5162">
               <id root="b3d0ebf0-f57e-4c1f-acf9-ed3757e38f65"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20240201"/>
               <component>
                  <section ID="ID_b05410c6-998c-4876-861e-dad1ee38743d">
                     <id root="27fd4394-5dd7-44e2-a2cc-7a446e914a17"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenicity and Mutagenesis</content>
                        </paragraph>
                        <paragraph>Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of Cefazolin in Dextrose Injection have not been performed.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Fertility studies conducted in rats subcutaneously administered cefazolin at doses of</paragraph>
                        <paragraph>2000 mg/kg/day (approximately 3 times the maximum recommended human dose based on body surface area comparison) showed no impairment of mating and fertility.</paragraph>
                     </text>
                     <effectiveTime value="20240201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3809e35c-e711-4baa-a6f3-5ba35a496734">
               <id root="360b68f3-ed04-4a7b-b6ed-72aee09c1f50"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES </title>
               <text>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>Czarny D, Prichard PJ, Fennessy M, Lewis S. Anaphylactoid reaction to 50% solution of dextrose. Med J Aust 1980;2:255-258.</item>
                     <item>
                        <caption>2.</caption>Guharoy, SR, Barajas M. Probably Anaphylactic Reaction to Corn-Derived Dextrose Solution. Vet Hum Toxicol 1991;33:609-610.</item>
                  </list>
               </text>
               <effectiveTime value="20210201"/>
            </section>
         </component>
         <component>
            <section ID="ID_1a3bf860-5bcd-472d-b101-046e57c24614">
               <id root="8ea4761c-ee38-430f-a8c6-ca41d99a941f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>Cefazolin in Dextrose Injection is supplied as a premixed, frozen, iso-osmotic, sterile, nonpyrogenic solution in single-dose Galaxy plastic containers as follows:</item>
                  </list>
                  <table styleCode="Noautorules" width="100%">
                     <col width="30%"/>
                     <col width="35%"/>
                     <col width="35%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Product Description</content>
                                 </item>
                              </list>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Number of Containers/Carton</content>
                                 </item>
                              </list>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">NDC Number</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>1 gram cefazolin in 50 mL (20 mg/mL)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>24 count</item>
                              </list>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>NDC 0338-3503-41</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>2 grams cefazolin in 100 mL (20 mg/mL)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>12 count</item>
                              </list>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>NDC 0338-3508-41</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>3 grams cefazolin in 150 mL (20 mg/mL)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>6 count</item>
                              </list>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>NDC 0338-0096-06</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store in a freezer capable of maintaining a temperature of -20°C (-4°F) or below.</paragraph>
                  <paragraph>Handle frozen product containers with care. Product containers may be fragile in the frozen state.</paragraph>
                  <paragraph>Thaw frozen container at room temperature 20°C to 25°C (68°F to 77°F) or under refrigeration 2°C to 8°C (36°F to 46°F). <content styleCode="underline">Do not force thaw by immersion in water baths or by microwave irradiation.</content>
                  </paragraph>
                  <paragraph>The thawed solution is stable for 30 days under refrigeration (5°C/41°F) or 48 hours at 25°C/77°F. <content styleCode="underline">Do not refreeze</content>
                     <content styleCode="italics"> [see <linkHtml href="#ID_f15627f6-7474-4cb2-92cd-0327db052096">Dosage and Administration (2.5)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20240531"/>
            </section>
         </component>
         <component>
            <section ID="ID_f290d106-d41b-49fa-9c2e-c7f70b8dfc53">
               <id root="83eaf62a-b63a-4988-877a-1953faf81c76"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Serious Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that allergic reactions, including serious allergic reactions could occur and that serious reactions require immediate treatment and discontinuation of Cefazolin in Dextrose Injection. Patients should report to their health care provider any previous allergic reactions to cefazolin, cephalosporins, penicillins, or other similar antibacterials.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Seizures</content>
                  </paragraph>
                  <paragraph>Advise patients that seizures could occur with Cefazolin in Dextrose Injection. Instruct patients to inform a healthcare provider at once of any signs and symptoms of seizures, for immediate treatment, dosage adjustment, or discontinuation of Cefazolin in Dextrose Injection.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Diarrhea</content>
                  </paragraph>
                  <paragraph>Advise patients that diarrhea is a common problem caused by antibacterials, which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterials. If this occurs, patients should contact a physician as soon as possible.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Antibacterial Resistance</content>
                  </paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs, including Cefazolin in Dextrose Injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefazolin in Dextrose Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefazolin in Dextrose Injection or other antibacterial drugs in the future.</paragraph>
               </text>
               <effectiveTime value="20240201"/>
            </section>
         </component>
         <component>
            <section ID="ID_3bc4ee37-b5d7-488a-8db3-34e809319c99">
               <id root="f36a07f9-8d39-4032-8131-221eec843881"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Baxter</content>
                     <br/>Baxter Healthcare Corporation<br/>Deerfield, IL 60015</paragraph>
                  <paragraph>Made in USA</paragraph>
                  <paragraph>07-19-05-386</paragraph>
                  <paragraph>Baxter and Galaxy are trademarks of Baxter International Inc. or its subsidiaries.</paragraph>
                  <paragraph>Any other trademarks, product brands or images appearing herein are the property of their respective owners.</paragraph>
               </text>
               <effectiveTime value="20240531"/>
            </section>
         </component>
         <component>
            <section ID="ID_3893a98b-7c4d-4405-b2d3-824d474fc87a">
               <id root="667ece3b-981c-4c89-895d-4a904cd716a6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <renderMultiMedia ID="id1737667540" referencedObject="ID_925f722d-8470-467b-b87b-eaaf4f71ab7e"/>
                  <renderMultiMedia ID="id656195435" referencedObject="C7B6158D-7EBA-4D09-97E5-558F8199394A">
                     <caption>Container Label</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">Cefazolin in Dextrose<br/>Injection, USP<br/>1 g / 50 mL<br/>
                     </content>(20 mg / mL)</paragraph>
                  <paragraph>
                     <content styleCode="bold">GALAXY <br/>Single Dose Container<br/>Discard unused portion</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-3503-41<br/>Code 2G3503<br/>Sterile Nonpyrogenic<br/>Iso-osmotic</content>
                  </paragraph>
                  <paragraph>Each 50 mL contains: 1 g Cefazolin, USP, equivalent to 1.05 g Cefazolin<br/>Sodium, USP with approx. 2 g Dextrose Hydrous, USP added to adjust<br/>osmolality, and Water for Injection, USP. pH may have been adjusted with<br/>sodium bicarbonate or sodium hydroxide/hydrochloric acid.</paragraph>
                  <paragraph>Dosage:  For Intravenous Infusion Only. See prescribing information.<br/>Cautions: Do not add supplementary medication or additives. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Store at or below -20°C (-4°F). Thaw at room temperature 20°C to 25°C (68°F to <br/>77°F) or under refrigeration 2°C to 8°C (36°F to 46°F). <content styleCode="bold">DO NOT FORCE<br/>THAW BY IMMERSION IN WATER BATHS OR BY MICROWAVE IRRADIATION.<br/>
                     </content>Thawed solution is stable for 30 days under refrigeration or 48 hours at room<br/>temperature. <content styleCode="bold">Do not refreeze.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>Baxter and Galaxy are registered trademarks of<br/>Baxter International Inc.<br/>Manufactured by <content styleCode="bold">Baxter Healthcare Corporation</content>
                     <br/>Deerfield, IL 60015 USA<br/>Made in US</paragraph>
                  <paragraph>PL2040 Plastic</paragraph>
                  <paragraph>07-34-00-1642</paragraph>
                  <paragraph>
                     <content styleCode="bold">* BAR CODE POSITION <br/>ONLY</content>
                  </paragraph>
                  <paragraph>303383503411</paragraph>
                  <renderMultiMedia ID="id-571114676" referencedObject="ID_1a3405b0-7153-4ab6-bcd2-166380d80e3e"/>
                  <renderMultiMedia ID="id1688860410" referencedObject="D82EFAF3-BF11-49EE-BDD1-C241FA12A024">
                     <caption>Carton Label</caption>
                  </renderMultiMedia>
                  <paragraph>Thaw at room temperature 20°C  to 25°C (68°F to 77°F) or under refrigeration 2°C  to 8°C (36°F to 41°F). <br/>
                     <content styleCode="bold">DO NOT FORCE THAW BY IMMERSION IN WATER BATHS OR BY MICROWAVE IRRADIATION.</content> Thawed solution is stable for 30 days under refrigeration or 48 hours at room temperature. <br/>
                     <content styleCode="bold">Do not refreeze.<br/>
                     </content>Handle frozen product containers with care. Product containers may be fragile in the<br/>frozen state.<br/>Baxter and Galaxy are registered trademarks of Baxter International Inc.<br/>PL 2040 Plastic</paragraph>
                  <paragraph>07-04-00-0801</paragraph>
                  <paragraph>
                     <content styleCode="bold">Cefazolin in Dextrose Injection, USP<br/>1 g / 50 mL </content>(20 mg / mL)<br/>Contains 12 units of Single Dose bags. Each bag contains 50 mL<content styleCode="bold"> Iso-osmotic</content>
                     <br/>
                     <content styleCode="bold">Store at or below -20°C (-4°F). Do not refreeze.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-3503-41<br/>Code 2G3503</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">*FOR BAR CODE POSITION ONLY<br/>(01) 20303383503415</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GALAXY </content>Container <br/>Sterile Nonpyrogenic<br/>Each 50 mL contains: 1g Cefazolin, USP, equivalent to 1.05 g Cefazolin Sodium, USP with approx. 2 g <br/>Dextrose Hydrous, USP added to adjust osmolality, and Water for Injection, USP. pH may have been adjusted<br/>with sodium bicarbonate or sodium hydroxide/hydrochloric acid.</paragraph>
                  <paragraph>Dosage: For Intravenous Infusion Only. See prescribing information.</paragraph>
                  <paragraph>Cautions: Do not add supplementary medications or additives.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>Baxter and Galaxy are registered trademarks of Baxter International, Inc.<content styleCode="bold">
                        <br/>Baxter Healthcare Corporation </content>Deerfield, IL 60015 USA</paragraph>
                  <renderMultiMedia ID="id1997608620" referencedObject="ID_1273a3fc-d0a3-416f-a490-300722907278"/>
                  <renderMultiMedia ID="id582115888" referencedObject="ID_41458a31-2881-4a2e-be40-f5eac25b24be">
                     <caption>Container Label</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">Cefazolin in Dextrose<br/>Injection, USP<br/>2 g / 100 mL<br/>
                     </content>(20 mg / mL)</paragraph>
                  <paragraph>
                     <content styleCode="bold">GALAXY <br/>Single Dose Container<br/>Discard unused portion</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-3508-41<br/>Code 2G3508<br/>Sterile Nonpyrogenic<br/>Iso-osmotic</content>
                  </paragraph>
                  <paragraph>Each 100 mL contains: 2 g Cefazolin, USP, equivalent to 2.1 g Cefazolin<br/>Sodium, USP with approx. 4 g Dextrose Hydrous, USP added to adjust<br/>osmolality, and Water for Injection, USP. pH may have been adjusted with<br/>sodium bicarbonate or sodium hydroxide/hydrochloric acid.</paragraph>
                  <paragraph>Dosage: For Intravenous Infusion Only. See prescribing information.<br/>Cautions: Do not add supplementary medication or additives. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Store at or below -20°C (-4°F). Thaw at room temperature 20°C to 25°C (68°F to <br/>77°F) or under refrigeration 2°C to 8°C (36°F to 46°F). <content styleCode="bold">DO NOT FORCE THAW<br/>BY IMMERSION IN WATER BATHS OR BY MICROWAVE IRRADIATION.</content> Thawed<br/>solution is stable for 30 days under refrigeration or 48 hours at room<br/>temperature. <content styleCode="bold">Do not refreeze.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>Baxter and Galaxy are registered trademarks of Baxter International Inc.<br/>Manufactured by <content styleCode="bold">Baxter Healthcare Corporation </content>Deerfield, IL 60015 USA<br/>Made in USA</paragraph>
                  <paragraph>PL2040 Plastic</paragraph>
                  <paragraph>07-34-00-1643</paragraph>
                  <paragraph>BAR CODE POSITION <br/>ONLY</paragraph>
                  <paragraph>303383508416</paragraph>
                  <renderMultiMedia ID="id907344040" referencedObject="ID_671e133e-29f5-4cb4-bf7f-3cd62ca6dd88"/>
                  <renderMultiMedia ID="id-1243102155" referencedObject="D2754E92-2788-426C-8651-325B827E2A5E">
                     <caption>Carton Label</caption>
                  </renderMultiMedia>
                  <paragraph>Thaw at room temperature 20°C  to 25°C (68°F to 77°F) or under refrigeration 2°C  to 8°C (36 °F to 41°F). <br/>
                     <content styleCode="bold">DO NOT FORCE THAW BY IMMERSION IN WATER BATHS OR BY MICROWAVE IRRADIATION.</content> Thawed solution is stable for 30 days under refrigeration or 48 hours at room temperature. <br/>
                     <content styleCode="bold">Do not refreeze.<br/>
                     </content>Handle frozen product containers with care. Product containers may be fragile in the<br/>frozen state.<br/>PL 2040 Plastic<br/>07-04-00-0802</paragraph>
                  <paragraph>
                     <content styleCode="bold">Cefazolin in Dextrose Injection, USP<br/>2 g / 100 mL</content> (20 mg/ mL)<br/>Contains 6 units of Single Dose bags. Each bag contains 100 mL. <content styleCode="bold">Iso-osmotic</content>
                     <br/>
                     <content styleCode="bold">Store at or below -20°C (4°F). Do not refreeze.<br/>
                     </content>Lot XXXXXX Exp. DD MMM YY</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-3508-41<br/>Code 2G3508</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">*FOR BAR CODE POSITION ONLY<br/>(01) 20303383508410</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GALAXY </content>Container <br/>Sterile Nonpyrogenic<br/>Each 100 mL contains: 2 g Cefazolin, USP, equivalent to 2.1 g Cefazolin Sodium, USP with approx. 4 g<br/>Dextrose Hydrous, USP added to adjust osmolality, and Water for Injection, USP. pH may have been<br/>adjusted with sodium bicarbonate or sodium hydroxide/hydrochloric acid.</paragraph>
                  <paragraph>Dosage: For Intravenous Infusion Only. See prescribing information.<br/>Cautions: Do not add supplementary medications or additives.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>Baxter and Galaxy are registered trademarks of Baxter International, Inc.<content styleCode="bold">
                        <br/>Baxter Healthcare Corporation </content>Deerfield, IL 60015 USA</paragraph>
                  <renderMultiMedia ID="id-1182204116" referencedObject="ID_9202da70-c82d-4374-9a82-ee1cfa8f898e"/>
                  <renderMultiMedia ID="id-1403600005" referencedObject="ID_36768f11-fab5-4dfc-abf0-4038cfa9c90d">
                     <caption>Container Label</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">Cefazolin<br/>in Dextrose Injection, USP<br/>3 g / 150 mL </content>(20 mg / mL)</paragraph>
                  <paragraph>
                     <content styleCode="bold">3 g</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GALAXY <br/>Single Dose Container<br/>Discard unused portion</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-0096-06<br/>Code 2G3509<br/>Sterile Nonpyrogenic<br/>Iso-osmotic</content>
                  </paragraph>
                  <paragraph>Each 150 mL contains: 3 g Cefazolin, USP, equivalent to<br/>3.15 g Cefazolin Sodium, USP with approx. 6 g Dextrose<br/>Hydrous, USP added to adjust osmolality, and Water for<br/>Injection, USP. pH may have been adjusted with sodium<br/>hydroxide or hydrochloric acid.</paragraph>
                  <paragraph>Dosage: For Intravenous Infusion Only. See prescribing <br/>information.</paragraph>
                  <paragraph>Caution: Do not add supplementary medication or additives. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Store at or below -20°C (-4°F). Thaw at room temperature <br/>20°C to 25°C (68°F to 77°F) or under refrigeration 2°C to 8°C <br/>(36°F to 46°F). <content styleCode="bold">DO NOT FORCE THAW BY IMMERSION <br/>IN WATER BATHS OR BY MICROWAVE IRRADIATION.</content>
                     <br/>Thawed solution is stable for 30 days under refrigeration<br/>or 48 hours at room temperature. <content styleCode="bold">Do not refreeze.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>Manufactured by <content styleCode="bold">Baxter Healthcare Corporation,<br/>
                     </content>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>PL2040 Plastic</paragraph>
                  <paragraph>07-34-00-1721</paragraph>
                  <paragraph>BAR CODE <br/>POSITION ONLY UPC-A</paragraph>
                  <paragraph>303380096060</paragraph>
                  <renderMultiMedia ID="id-865829646" referencedObject="A989132F-7924-41D4-A094-204D6D78F07F"/>
                  <renderMultiMedia ID="id-952011952" referencedObject="ID_44d21144-70e3-406e-8ba9-2748b9427090">
                     <caption>Carton Label</caption>
                  </renderMultiMedia>
                  <paragraph>Thaw at room temperature 20°C to 25°C (68°F to 77°F) or under refrigeration 2°C to 8°C (36 °F to 41°F). <br/>
                     <content styleCode="bold">DO NOT FORCE THAW BY IMMERSION IN WATER BATHS OR BY MICROWAVE IRRADIATION.</content> Thawed solution is stable for 30 days under refrigeration or 48 hours at room temperature. <br/>
                     <content styleCode="bold">Do not refreeze.<br/>
                     </content>Handle frozen product containers with care. Product containers may be fragile in the frozen state.</paragraph>
                  <paragraph>PL 2040 Plastic</paragraph>
                  <paragraph>07-04-00-0843</paragraph>
                  <paragraph>
                     <content styleCode="bold">Cefazolin<br/>in Dextrose Injection, USP<br/>3 g / 150 mL </content>(20 mg / mL)</paragraph>
                  <paragraph>
                     <content styleCode="bold">3 g</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>Contains 3 units of Single-Dose bags.<br/>Each bag contains 150 mL.<br/>
                     <content styleCode="bold">Store at or below -20°C (-4°F). Do not refreeze.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-0096-06<br/>Code 2G3509</content>
                  </paragraph>
                  <paragraph>*FOR BAR CODE POSITION ONLY<br/>(01) 20303380096064</paragraph>
                  <paragraph>
                     <content styleCode="bold">GALAXY </content>Container <br/>Sterile Nonpyrogenic<br/>Each 150 mL contains: 3 g Cefazolin, USP, equivalent to 3.15 g Cefazolin Sodium, USP with approx. 6 g Dextrose Hydrous, USP added to adjust osmolality, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide or hydrochloric acid.<br/>Dosage: For Intravenous Infusion Only. See prescribing information<br/>Caution: Do not add supplementary medications or additives.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation </content>Deerfield, IL 60015 USA</paragraph>
               </text>
               <effectiveTime value="20240531"/>
               <component>
                  <observationMedia ID="ID_925f722d-8470-467b-b87b-eaaf4f71ab7e">
                     <text>Representative Cefazolin Container Label 0338-3503-41 1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="C7B6158D-7EBA-4D09-97E5-558F8199394A">
                     <text>Representative Cefazolin Container Label 0338-3503-41 2 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_1a3405b0-7153-4ab6-bcd2-166380d80e3e">
                     <text>Representative Cefazolin Carton Label 0338-3503-41  1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="D82EFAF3-BF11-49EE-BDD1-C241FA12A024">
                     <text>Representative Cefazolin Carton Label 0338-3503-41  2 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_1273a3fc-d0a3-416f-a490-300722907278">
                     <text>Representative Cefazolin Container Label 0338-3508-41 1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_41458a31-2881-4a2e-be40-f5eac25b24be">
                     <text>Representative Cefazolin Container Label 0338-3508-41 2 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_671e133e-29f5-4cb4-bf7f-3cd62ca6dd88">
                     <text>Representative Cefazolin Carton Label 0338-3508-41  1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="D2754E92-2788-426C-8651-325B827E2A5E">
                     <text>Representative Cefazolin Carton Label 0338-3508-41  1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_9202da70-c82d-4374-9a82-ee1cfa8f898e">
                     <text>Representative Cefazolin Container Label 0338-0096-06 1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_36768f11-fab5-4dfc-abf0-4038cfa9c90d">
                     <text>Representative Cefazolin Container Label 0338-0096-06 2 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="A989132F-7924-41D4-A094-204D6D78F07F">
                     <text>Representative Cefazolin Carton Label 0338-0096-06  1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_44d21144-70e3-406e-8ba9-2748b9427090">
                     <text>Representative Cefazolin Carton Label 0338-0096-06  2 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>